Small molecule · Inhibitor of dihydroorotate dehydrogenase (DHODH) · developed by Immunic
Vidofludimus is an orally bioavailable inhibitor of the mitochondrial enzyme dihydroorotate dehydrogenase (DHODH), which blocks de novo pyrimidine synthesis in activated lymphocytes and reduces release of inflammatory cytokines such as IL-17 and IFN-gamma. It is studied in relapsing-remitting multiple sclerosis and COVID-19.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05134441 | Phase 3 | Multiple Sclerosis | Active not recruiting | IMUX |
| NCT04379271 | Phase 2/3 | COVID-19 | Completed | IMUX |
| NCT03846219 | Phase 2 | Relapsing-Remitting Multiple Sclerosis (RRMS) | Active not recruiting | IMUX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Multiple Sclerosis, Relapsing-RemittingRelapsing-Remitting Multiple Sclerosis (RRMS)COVID-19
Updated Nov 15, 2026. Something wrong or missing? Report it on the IMUX page.
See IMUX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
IMUX catalysts and pipeline →